Omada Health reported full-year revenue of $260 million, up 53% from 2024, and fourth-quarter revenue of $76 million, up 58% year-over-year. Total membership reached 886,000, a 55% increase, while fourth-quarter net income was $5 million versus a $8 million loss and adjusted EBITDA improved to $8 million. Cash and cash equivalents stood at $222 million at year-end.

In March 2026, the company launched GLP-1 Flex Care, a cash-pay employer program offering clinical evaluation, prescription management, medication titration, side-effect support, nutrition and activity counseling, and discontinuation guidance. Employers gain a structured obesity care pathway without open-ended medication coverage as employees purchase GLP-1 drugs independently through cash-pay channels while receiving virtual medical oversight.

Omada has supported over 150,000 members on GLP-1 therapies and built its Flex Care on a proven GLP-1 care track. A 12-month analysis showed 67% of participants remained on medication compared with 47–49% in real-world benchmarks, and those who persisted achieved average weight loss of 18.4% at one year versus 11.9%, maintaining results after discontinuation.